The 2012 NCDEU Poster Session was published in June 2012 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2012. The latest review of this material was May 2012.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
After completing this educational activity, you should be able to:
This special 2012 NCDEU Poster Session was developed based on our assessment of the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on current research relevant to clinical practice.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:
Dr Baker is an employee of Otsuka.
Dr Berman is an employee and stock shareholder of Bristol-Myers Squibb.
Dr Casey is a consultant for Abbott, Bristol-Myers Squibb, Dainippon Sumitomo, Genetech, Janssen, Merck, NuPathe, Pfizer, Solvay, and Wyeth and has received honoraria from and is a member of the speakers/advisory boards for Abbott, Bristol-Myers Squibb, Janssen, Merck, and Pfizer.
Mr Eudicone is an employee of Bristol-Myers Squibb.
Dr Fayyad is an employee and stock shareholder of Pfizer.
Dr Guico-Pabia is an employee of Pfizer.
Dr Krystal is a consultant for Aisling Capital, Astellas, AstraZeneca, Biocortech, Brintnall & Nicolini, Easton Associates, Gilead Sciences, GlaxoSmithKline, Janssen, Lundbeck, Medivation, Merz, MK Medical Communications, F. Hoffman-La Roche, Sage Therapeutics, SK Holdings, Sunovion, Takeda, and Teva; is a member of the scientific advisory boards for Abbott, Bristol-Myers Squibb, CHDI Foundation, Eisai, Eli Lilly, Forest, Lohocla, Mnemosyne, Naurex, Pfizer, Shire, and StratNeuro Research Program (Karolinska Institute); is a member of the board of directors of the Coalition for Translational Research in Alcohol and Substance Use Disorders; is the president of the American College of Neuropsychopharmacology; and is a member of the editorial board for Biological Psychiatry.
Dr Laubmeier is an employee of Otsuka.
Dr Mallinckrodt is an employee and stock shareholder of Eli Lilly.
Dr Marcus is an employee and stock shareholder of Bristol-Myers Squibb.
Dr O’Gorman is an employee and stock shareholder of Pfizer.
Dr Sheehan is an employee of Bristol-Myers Squibb.
Dr Soares is a consultant for Eli Lilly, Pfizer, Lundbeck, Noven, Bristol-Myers Squibb, and AstraZeneca; has received grant/research support from the Canadian Institutes of Health Research, NARSAD, Pfizer, and Eli Lilly; has received honoraria from AstraZeneca, Pfizer, and Lundbeck; and is a member of the speakers/advisory boards for AstraZeneca, Pfizer, Lundbeck, and Noven.
Drs Castellanos, Coffey, Gabbay, Gueorguieva, Milham, and Shungu; Mr Ely; and Ms Kang have no personal affiliations or financial relationships with any commercial interest to disclose relative to this presentation.
In this 2012 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This 2012 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP).
This 2012 NCDEU Poster Session is derived from the 52nd Annual NCDEU Meeting, which was held May 29–June 1, 2012, in Phoenix, Arizona, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.